• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乙醇脱氢酶1B促进间皮清除和卵巢癌浸润。

ADH1B promotes mesothelial clearance and ovarian cancer infiltration.

作者信息

Gharpure Kshipra M, Lara Olivia D, Wen Yunfei, Pradeep Sunila, LaFargue Chris, Ivan Cristina, Rupaimoole Rajesha, Hu Wei, Mangala Lingegowda S, Wu Sherry Y, Nagaraja Archana S, Baggerly Keith, Sood Anil K

机构信息

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

出版信息

Oncotarget. 2018 May 18;9(38):25115-25126. doi: 10.18632/oncotarget.25344.

DOI:10.18632/oncotarget.25344
PMID:29861857
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5982754/
Abstract

Primary debulking surgery followed by adjuvant chemotherapy is the standard treatment for ovarian cancer. Residual disease after primary surgery is associated with poor patient outcome. Previously, we discovered ADH1B to be a molecular biomarker of residual disease. In the current study, we investigated the functional role of ADH1B in promoting ovarian cancer cell invasiveness and contributing to residual disease. We discovered that ADH1B overexpression leads to a more infiltrative cancer cell phenotype, promotes metastasis, increases the adhesion of cancer cells to mesothelial cells, and increases extracellular matrix degradation. Live cell imaging revealed that ADH1B-overexpressing cancer cells efficiently cleared the mesothelial cell layer compared to control cells. Moreover, gene array analysis revealed that ADH1B affects several pathways related to the migration and invasion of cancer cells. We also discovered that hypoxia increases ADH1B expression in ovarian cancer cells. Collectively, these findings indicate that ADH1B plays an important role in the pathways that promote ovarian cancer cell infiltration and may increase the likelihood of residual disease following surgery.

摘要

原发性肿瘤细胞减灭术联合辅助化疗是卵巢癌的标准治疗方法。初次手术后的残留病灶与患者预后不良相关。此前,我们发现ADH1B是残留病灶的分子生物标志物。在本研究中,我们调查了ADH1B在促进卵巢癌细胞侵袭及导致残留病灶方面的功能作用。我们发现,ADH1B的过表达导致癌细胞表型更具浸润性,促进转移,增加癌细胞与间皮细胞的黏附,并增加细胞外基质降解。活细胞成像显示,与对照细胞相比,过表达ADH1B的癌细胞能有效清除间皮细胞层。此外,基因芯片分析显示,ADH1B影响与癌细胞迁移和侵袭相关的多个通路。我们还发现,缺氧会增加卵巢癌细胞中ADH1B的表达。总体而言,这些发现表明,ADH1B在促进卵巢癌细胞浸润的通路中起重要作用,并可能增加术后残留病灶的可能性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d60/5982754/f4610d6a0335/oncotarget-09-25115-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d60/5982754/14e717cd5a06/oncotarget-09-25115-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d60/5982754/82b03a702f9d/oncotarget-09-25115-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d60/5982754/edf04c6404c9/oncotarget-09-25115-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d60/5982754/f4610d6a0335/oncotarget-09-25115-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d60/5982754/14e717cd5a06/oncotarget-09-25115-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d60/5982754/82b03a702f9d/oncotarget-09-25115-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d60/5982754/edf04c6404c9/oncotarget-09-25115-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d60/5982754/f4610d6a0335/oncotarget-09-25115-g004.jpg

相似文献

1
ADH1B promotes mesothelial clearance and ovarian cancer infiltration.乙醇脱氢酶1B促进间皮清除和卵巢癌浸润。
Oncotarget. 2018 May 18;9(38):25115-25126. doi: 10.18632/oncotarget.25344.
2
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
3
Optimal primary surgical treatment for advanced epithelial ovarian cancer.晚期上皮性卵巢癌的最佳初次手术治疗
Cochrane Database Syst Rev. 2011 Aug 10;2011(8):CD007565. doi: 10.1002/14651858.CD007565.pub2.
4
Interventions for fertility preservation in women with cancer undergoing chemotherapy.对接受化疗的癌症女性进行生育力保存的干预措施。
Cochrane Database Syst Rev. 2025 Jun 19;6:CD012891. doi: 10.1002/14651858.CD012891.pub2.
5
Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.超根治性(广泛)手术与标准手术治疗晚期上皮性卵巢癌的初步细胞减灭术。
Cochrane Database Syst Rev. 2022 Aug 30;8(8):CD007697. doi: 10.1002/14651858.CD007697.pub3.
6
Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).针对接受体外受精加卵胞浆内单精子注射(IVF/ICSI)的女性,使用卵巢储备标志物进行个性化促性腺激素剂量选择。
Cochrane Database Syst Rev. 2018 Feb 1;2(2):CD012693. doi: 10.1002/14651858.CD012693.pub2.
7
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.紫杉烷类单药治疗方案用于复发性上皮性卵巢癌。
Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD008766. doi: 10.1002/14651858.CD008766.pub3.
8
Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.早期上皮性卵巢癌的辅助(术后)化疗。
Cochrane Database Syst Rev. 2012 Mar 14;3(3):CD004706. doi: 10.1002/14651858.CD004706.pub4.
9
Agents for ovarian stimulation for intrauterine insemination (IUI) in ovulatory women with infertility.用于排卵障碍性不孕患者宫腔内人工授精的促排卵药物。
Cochrane Database Syst Rev. 2021 Nov 5;11(11):CD005356. doi: 10.1002/14651858.CD005356.pub3.
10
LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.促黄体生成素释放激素激动剂用于绝经前女性早期乳腺癌的辅助治疗。
Cochrane Database Syst Rev. 2009 Oct 7;2009(4):CD004562. doi: 10.1002/14651858.CD004562.pub4.

引用本文的文献

1
DFASGCNS: A prognostic model for ovarian cancer prediction based on dual fusion channels and stacked graph convolution.DFASGCNS:基于双融合通道和堆叠图卷积的卵巢癌预测预后模型。
PLoS One. 2024 Dec 16;19(12):e0315924. doi: 10.1371/journal.pone.0315924. eCollection 2024.
2
High-grade serous carcinoma of the fallopian tube in a young woman with chromosomal 4q abnormality: A case report.一名年轻女性患有4号染色体异常的高级别输卵管浆液性癌:病例报告
World J Clin Cases. 2024 Jun 26;12(18):3539-3547. doi: 10.12998/wjcc.v12.i18.3539.
3
A Recipe for Successful Metastasis: Transition and Migratory Modes of Ovarian Cancer Cells.

本文引用的文献

1
Expression levels of seprase/FAPα and DPPIV/CD26 in epithelial ovarian carcinoma.上皮性卵巢癌中seprase/FAPα和DPPIV/CD26的表达水平。
Oncol Lett. 2015 Jul;10(1):34-42. doi: 10.3892/ol.2015.3151. Epub 2015 Apr 27.
2
The homeoprotein DLX4 stimulates NF-κB activation and CD44-mediated tumor-mesothelial cell interactions in ovarian cancer.同源异型蛋白DLX4可刺激卵巢癌中NF-κB的激活以及CD44介导的肿瘤-间皮细胞相互作用。
Am J Pathol. 2015 Aug;185(8):2298-308. doi: 10.1016/j.ajpath.2015.04.004. Epub 2015 Jun 9.
3
Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer.
成功转移的秘诀:卵巢癌细胞的转变和迁移模式
Cancers (Basel). 2024 Feb 15;16(4):783. doi: 10.3390/cancers16040783.
4
Identification of a short, single site matriglycan that maintains neuromuscular function in the mouse.在小鼠中鉴定出一种维持神经肌肉功能的短链单位点基质聚糖。
bioRxiv. 2023 Dec 21:2023.12.20.572361. doi: 10.1101/2023.12.20.572361.
5
Targeting metabolic fluxes reverts metastatic transitions in ovarian cancer.靶向代谢通量可逆转卵巢癌的转移转变。
iScience. 2023 Sep 28;26(11):108081. doi: 10.1016/j.isci.2023.108081. eCollection 2023 Nov 17.
6
Omentum provides a special cell microenvironment for ovarian cancer.大网膜为卵巢癌提供了特殊的细胞微环境。
Cancer Rep (Hoboken). 2023 Oct;6(10):e1858. doi: 10.1002/cnr2.1858. Epub 2023 Aug 21.
7
Identification of copper metabolism-related subtypes and establishment of the prognostic model in ovarian cancer.鉴定卵巢癌中与铜代谢相关的亚型并建立预后模型。
Front Endocrinol (Lausanne). 2023 Mar 6;14:1145797. doi: 10.3389/fendo.2023.1145797. eCollection 2023.
8
Survival Analysis with High-Dimensional Omics Data Using a Threshold Gradient Descent Regularization-Based Neural Network Approach.基于阈值梯度下降正则化的神经网络方法对高维组学数据进行生存分析。
Genes (Basel). 2022 Sep 19;13(9):1674. doi: 10.3390/genes13091674.
9
The Transcoelomic Ecosystem and Epithelial Ovarian Cancer Dissemination.腔道转移生态系统与上皮性卵巢癌扩散
Front Endocrinol (Lausanne). 2022 Apr 28;13:886533. doi: 10.3389/fendo.2022.886533. eCollection 2022.
10
Identification of Potential Biomarkers and Small Molecule Drugs for Cutaneous Melanoma Using Integrated Bioinformatic Analysis.利用综合生物信息学分析鉴定皮肤黑色素瘤的潜在生物标志物和小分子药物
Front Cell Dev Biol. 2022 Mar 30;10:858633. doi: 10.3389/fcell.2022.858633. eCollection 2022.
CD44在卵巢癌转移、复发及耐药发生过程中的上调。
Oncotarget. 2015 Apr 20;6(11):9313-26. doi: 10.18632/oncotarget.3220.
4
A framework for a personalized surgical approach to ovarian cancer.一种针对卵巢癌的个性化手术方法的框架。
Nat Rev Clin Oncol. 2015 Apr;12(4):239-45. doi: 10.1038/nrclinonc.2015.26. Epub 2015 Feb 24.
5
Expression and significance of CD44, CD47 and c-met in ovarian clear cell carcinoma.CD44、CD47和c-met在卵巢透明细胞癌中的表达及意义
Int J Mol Sci. 2015 Feb 4;16(2):3391-404. doi: 10.3390/ijms16023391.
6
The C3G/Rap1 pathway promotes secretion of MMP-2 and MMP-9 and is involved in serous ovarian cancer metastasis.C3G/Rap1信号通路促进基质金属蛋白酶-2(MMP-2)和基质金属蛋白酶-9(MMP-9)的分泌,并参与浆液性卵巢癌转移。
Cancer Lett. 2015 Apr 10;359(2):241-9. doi: 10.1016/j.canlet.2015.01.019. Epub 2015 Jan 21.
7
Alcohol dehydrogenase-1B Arg47His polymorphism is associated with head and neck cancer risk in Asian: a meta-analysis.酒精脱氢酶-1B基因Arg47His多态性与亚洲人头颈部癌症风险的相关性:一项荟萃分析
Tumour Biol. 2015 Feb;36(2):1023-7. doi: 10.1007/s13277-014-2727-x. Epub 2014 Oct 17.
8
Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion.间皮细胞通过分泌纤连蛋白促进早期卵巢癌转移。
J Clin Invest. 2014 Oct;124(10):4614-28. doi: 10.1172/JCI74778. Epub 2014 Sep 9.
9
Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer.肿瘤细胞产生的基质金属蛋白酶9(MMP-9)驱动基底样三阴性乳腺癌的恶性进展和转移。
Oncotarget. 2014 May 15;5(9):2736-49. doi: 10.18632/oncotarget.1932.
10
Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance.表达间充质基因程序的卵巢癌细胞球表现出增强的间皮清除能力。
J Clin Invest. 2014 Jun;124(6):2611-25. doi: 10.1172/JCI69815. Epub 2014 Apr 24.